NPPA Revises Oxaliplatin Injection Ceiling Price Under DPCO 2013

Notification/Circular No.: S.O. 6001(E) dated November 2, 2026; S.O. 1394(E) dated May 30, 2013; S.O. 5249(E) dated November 11, 2022; Review Order 31015/39/2023-Pricing (E-23351) dated March 30, 2026; S.O. 1575(E) dated March 25, 2026 (Sl. No. 562)

Applicable Act/Rule: Drugs (Prices Control) Order, 2013; Essential Commodities Act, 1955; National List of Essential Medicines, 2022

Applicable Section/Rule: DPCO, 2013 paragraphs 4, 6, 10, 11, 14, 16, 17, 18 and 31; paragraph 13(2); paragraph 24 and 24(4); paragraph 2(1)(u); Schedule II Forms I, III and IV; Form V

Effective Period: From November 2, 2026 (date of notification)

The National Pharmaceutical Pricing Authority (NPPA) has issued S.O. 6001(E) fixing/revising the ceiling price for a scheduled formulation under the Drugs (Prices Control) Order, 2013, pursuant to a Department of Pharmaceuticals review order under paragraph 31. The order applies to Oxaliplatin Injection 5 mg/mL in 10 mL vial and incorporates the Wholesale Price Index impact of 0.64956% for the year 2026.

NPPA has set the revised ceiling price, exclusive of Goods and Services Tax, at Rs. 2285.84 per 1 vial for Oxaliplatin Injection 5 mg/mL in 10 mL vial, against the earlier NLEM 2022 ceiling price of Rs. 2287.59. Manufacturers selling branded or generic versions above the notified ceiling price must reduce prices so they do not exceed the revised ceiling price plus applicable GST. Manufacturers already pricing below the ceiling must maintain their existing MRP in accordance with paragraph 13(2) of the DPCO, 2013. GST may be added only if actually paid or payable on the ceiling price.

The ceiling price for any pack must be derived as per paragraph 11 of the DPCO, 2013, and manufacturers must issue a price list in Form V from the date of notification via IPDMS to NPPA, with a copy to the State Drug Controller and dealers under paragraph 24. Every retailer and dealer is required to display the price list and any supplementary price list at a conspicuous part of their premises so it is easily accessible for reference, as per paragraph 24(4). If an existing manufacturer introduces a new drug as defined in paragraph 2(1)(u), it must seek prior price approval by applying in Form I under Schedule II of the DPCO, 2013.

Manufacturers must submit monthly returns on production/import and sale of the scheduled formulation in Schedule II Form III through IPDMS. Any intent to discontinue production and/or import of the scheduled formulation must be notified to NPPA in Schedule II Form IV at least six months in advance. Non-compliance with the notified ceiling price and related provisions will attract liability to deposit the overcharged amount along with interest under the DPCO, 2013 read with the Essential Commodities Act, 1955. This order supersedes the earlier NPPA order cited as S.O. 1575(E) dated March 25, 2026.

Link: https://egazette.gov.in/WriteReadData/2026/277613.pdf

Disclaimer: The information contained in this Article is intended solely for personal non-commercial use of the user who accepts full responsibility of its use. The information in the article is general in nature and should not be considered to be legal, tax, accounting, consulting or any other professional advice. We make no representation or warranty of any kind, express or implied regarding the accuracy, adequacy, reliability or completeness of any information on our page/article.

To stay updated Subscribe to our newsletter today

Explore other Legal updates on the Corplico and follow us on LinkedIn to stay updated

Post Views: 25

Schedule A Demo